Phase 2 Trial Results for CMV-Specific TCR-T Cell Therapy

25 patients were enrolled in a phase 2 clinical trial evaluating CMV-specific T-cell receptor-engineered T-cell therapy. The trial, registered as NCT05140187, reports a 4-week complete remission rate of 92.3% among 13 treated patients, with a median follow-up of 1011 days. The results document the efficacy and safety of this first-line therapy for cytomegalovirus reactivation after haploidentical hematopoietic stem cell transplantation.

Use Cases

• Analyze clinical efficacy metrics based on reported complete remission rates and patient follow-up durations.
• Study safety profiles based on reported instances of cytokine release syndrome.
• Model T-cell expansion dynamics based on reported TCR copy number increases.
• Compare first-line treatment outcomes based on the described therapy protocol and salvage therapy criteria.

Strengths

• Includes specific clinical outcomes: 92.3% 4-week complete remission rate among 13 treated patients.
• Provides longitudinal data with a median patient follow-up of 1011 days post-infusion.
• Reports precise dosing and treatment criteria, such as infusion of 5 × 10^5 cells/kg.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect temporal or cohort bias inherent to a single clinical trial.

Provenance

Source

Author: Jingwen Tang. Platform: figshare.

Collection Method

Data was collected as part of a registered phase 2 clinical trial (NCT05140187).

Time Range

The trial follow-up period extended to at least 1561 days post-infusion.

Freshness

Last updated 2026-05-14 05:43:33; freshness should be verified.